TVRD · Tvardi Therapeutics, Inc.
$1.08
-0.02 (-1.82%)
At close · Oct 8
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$14.67M
Shares
13.34M
Volume · Oct 8
160.04K
Avg daily vol (3M)
533.47K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.08
Open$1.10
Day$1.04–1.10
52W close$1.06–42.98
Avg vol 30d206K
Short int256K · 1.9% float · 2.3d
Short vol56%
Last earningsAug 19, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Jan 6, 2027
Est · unconfirmed
· in 13 wks
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$7.57M
Trailing 12 months
Net income (TTM)
−$26.06M
Trailing 12 months
Revenue growth YoY
+20.3%
Year over year
Operating margin
-393.8%
Trailing 12 months
P / E (TTM)
27.5
Trailing earnings · reciprocal yield 3.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.0%
Year over year · more shares
Price change (1Y)
-97.3%
Trailing year
Short interest
1.9%
Latest settlement · 2.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−64%
below
Price vs 50-day avg
−36%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−41%
trailing
6-month return
−68%
trailing
YTD return
−75%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
2 of 57 funds reported for Sep 30 · net +944 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.92% of float · ▼ -3.6% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 4-yr range
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
+959%
Y/Y
EPS growth
+71%
Y/Y
Free cash flow
$-24.5M
Quant / Vol
risk profile
Volatility
147%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
12.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−64%
Bearish
Price vs 50-day avg
−36%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
2 of 57 funds reported for Sep 30 · net +944 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.92% of float · ▼ -3.6% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 4-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $43
vs 200-day avg -64%
vs 50-day avg -36%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TVRD
this stock
Tvardi Therapeutics, Inc.
|
$14.67M | -74.9% | +959.3% | — | 1.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.0% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TVRD | -12.9% | -41.1% | -68.1% | -13.6% | -74.9% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -14.2% | -43.3% | -77.1% | -15.1% | -88.4% |